Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Jul;10(7):1657-1660.
doi: 10.1111/1759-7714.13127. Epub 2019 Jun 26.

Osimertinib-induced severe interstitial lung disease: A case report

Mengdi Fan  1 , Ting Mo  2 , Lulei Shen  2 , Li Yang  2
Affiliations
Case Reports

Osimertinib-induced severe interstitial lung disease: A case report

Mengdi Fan et al. Thorac Cancer. 2019 Jul.

Abstract

Lung cancer is globally one of the leading causes of malignant tumor-related mortality and ranks as having the highest incidence found in men and second in women. Osimertinib is a drug used to target lung cancer but its toxicity is not fully understood. Here we present a case of lung adenocarcinoma in a 78-year-old man that was treated and responded favorably with Osimertinib after the failure of other therapies. Unfortunately, the patient developed severe interstitial lung disease during the treatment procedure.

Keywords: Carcinoma of the lung; interstitial lung disease; osimertinib; prognosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CT scan of the chest showed a pulmonary space‐occupying lesion in the left upper lobe highly suspicious of lung cancer. (a) A pulmonary space‐occupying lesion is visible in the left upper lobe. (b) Bilateral subpleural line of the lung indicated by red arrows.
Figure 2
Figure 2
Following fine needle biopsy, pathology confirmed a diagnosis of lung adenocarcinoma with EGFR mutation. (a) Pathology demonstrated lung adenocarcinoma, original magnification ×200. (b) Indicates EGFR exon 19 mutation with 19‐deletion (19‐Del) .
Figure 3
Figure 3
Immunofluorescence assay indicated the ALK ROS1 was negative. (a) ALK control. (b) Case of the ALK examination. (c) Control of ROS1 examination. (d) Case of the ROS1 examination.
Figure 4
Figure 4
Chest CT before and after osimertinib treatment. (a) A round space‐occupying lesion with surrounding ground‐glass opacity was seen (indicated by red arrow) before osimertinib treatment. (b) A complete response after osimertinib treatment was achieved although severe interstitial lung disease was visible.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69: 7–34. - PubMed
    1. Zheng R, Zeng H, Zhang S, Chen T, Chen W. National estimates of cancer prevalence in China, 2011. Cancer Lett 2016; 370: 33–8. - PubMed
    1. Lee SM, Khan I, Upadhyay S et al First‐line erlotinib in patients with advanced non‐small‐cell lung cancer unsuitable for chemotherapy (TOPICAL): A double‐blind, placebo‐controlled, phase 3 trial. Lancet Oncol 2012; 13: 1161–70. - PMC - PubMed
    1. Sonehara K, Kobayashi T, Tateishi K et al Clinical analysis of EGFR‐positive non‐small cell lung cancer patients treated with first‐line afatinib: A Nagano lung cancer research group. Thorac Cancer 2019; 10: 1078–85. - PMC - PubMed
    1. Jänne PA, Yang JC, Kim DW et al AZD9291 in EGFR inhibitor‐resistant non‐small‐cell lung cancer. N Engl J Med 2015; 372: 1689–99. - PubMed

Publication types

MeSH terms